Multiple-dose Tolerability and Pharmacokinetic of IBI362 in Chinese Patients With T2DM
Condition: Type 2 Diabetes Interventions: Drug: IBI362; Drug: Placebo; Drug: Dulaglutide Sponsor: Innovent Biologics (Suzhou) Co. Ltd. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials